METTL14 and myelodysplastic syndrome: Collectively, m6A level and METTL14 expression were elevated in MDS with bone marrow blasts ≥ 5%, and significantly associated with disease risks and clinical outcomes, suggesting that METTL14 may play crucial roles in the pathogenesis of MDS.